Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 3;35(5):2543–2552. doi: 10.3892/or.2016.4653

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Yoshikawa et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

The effects of PRIMA-1^MET on tumor cell growth in ovarian cancer cells. (a) PRIMA-1^MET-induced growth suppressive dose response curves of EOC cells following 48 h of PRIMA-1^MET treatment. The IC₅₀ values of PRIMA-1^MET were determined in a total of 9 EOC cell lines by cell viability assay. Data represent the mean ± standard deviation (SD) from triplicate reactions. (b) Correlation between PRIMA-1^MET 48 h IC₅₀ values and TP53 status. EOC cell lines with wild-type p53 were slightly more sensitive than those with mutant p53 (not significant). (c) PRIMA-1^MET-induced morphological changes in EOC cells. ES-2, OVCAR-3, and SKOV-3 cells were cultured in a 6-well plate, and then treated with 0, 50, 100 µM PRIMA-1^MET for 24 h. PRIMA-1^MET-induced morphological changes were observed using microscopy (scale bar, 200 µm). (d) PRIMA-1^MET-induced growth suppressive dose response curves of NOS2, NOS3, and their chemo-resistant cells. The IC₅₀ values of 48 h PRIMA-1^MET were determined by cell viability assay. Data displays mean ± standard deviation (SD) from triplicate reactions.